| A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function (NCT04056468) | Millennium Pharmaceuticals, Inc. | 2020-10-09 |
| Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants (NCT04454918) | Millennium Pharmaceuticals, Inc. | 2020-07-30 |
| A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys (NCT04056455) | Millennium Pharmaceuticals, Inc. | 2020-03-04 |
| A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia (NCT04091438) | Millennium Pharmaceuticals, Inc. | 2020-01-26 |
| Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT04051827) | Millennium Pharmaceuticals, Inc. | 2019-12-23 |
| Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP) (NCT04091425) | Millennium Pharmaceuticals, Inc. | 2019-11-21 |
| A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants (NCT04121078) | Millennium Pharmaceuticals, Inc. | 2019-10-15 |
| Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS) (NCT03990649) | Millennium Pharmaceuticals, Inc. | 2019-07-23 |
| A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants (NCT03928327) | Millennium Pharmaceuticals, Inc. | 2019-05-02 |
| A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors (NCT03708211) | Millennium Pharmaceuticals, Inc. | 2019-03-28 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants (NCT03870555) | Millennium Pharmaceuticals, Inc. | 2019-03-08 |
| A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants (NCT03849690) | Millennium Pharmaceuticals, Inc. | 2019-02-27 |
| Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation (NCT03657160) | Millennium Pharmaceuticals, Inc. | 2019-02-06 |
| Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) (NCT03748953) | Millennium Pharmaceuticals, Inc. | 2019-01-24 |
| A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants (NCT03811834) | Millennium Pharmaceuticals, Inc. | 2019-01-22 |
| A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis (NCT03544229) | Millennium Pharmaceuticals, Inc. | 2018-10-14 |
| TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI) (NCT03477903) | Millennium Pharmaceuticals, Inc. | 2018-08-25 |
| A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors (NCT03486314) | Millennium Pharmaceuticals, Inc. | 2018-08-13 |
| A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease (NCT03701555) | Millennium Pharmaceuticals, Inc. | 2018-06-19 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants (NCT03501069) | Millennium Pharmaceuticals, Inc. | 2018-05-30 |
| A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants (NCT03500224) | Millennium Pharmaceuticals, Inc. | 2018-04-30 |
| A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC) (NCT03449030) | Millennium Pharmaceuticals, Inc. | 2018-04-23 |
| A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) (NCT03439280) | Millennium Pharmaceuticals, Inc. | 2018-04-20 |
| A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants (NCT03482453) | Millennium Pharmaceuticals, Inc. | 2018-03-28 |
| Efficacy and Safety of TAK-653 in Treatment-Resistant Depression (NCT03312894) | Millennium Pharmaceuticals, Inc. | 2018-02-15 |
| A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors (NCT03330106) | Millennium Pharmaceuticals, Inc. | 2017-11-15 |
| A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors (NCT03261947) | Millennium Pharmaceuticals, Inc. | 2017-10-25 |
| A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG) (NCT03268941) | Millennium Pharmaceuticals, Inc. | 2017-09-26 |